Radiopharmaceuticals

"Radiopharmaceuticals" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

Compounds that are used in medicine as sources of radiation for radiotherapy and for diagnostic purposes. They have numerous uses in research and industry. (Martindale, The Extra Pharmacopoeia, 30th ed, p1161)

Descriptor ID	D019275
MeSH Number(s)	D27.505.259.843 D27.505.519.871 D27.720.470.410.650
Concept/Terms	Radiopharmaceuticals Radiopharmaceuticals

Below are MeSH descriptors whose meaning is more general than "Radiopharmaceuticals".

Chemicals and Drugs [D]
Chemical Actions and Uses [D27]
Pharmacologic Actions [D27.505]
Diagnostic Uses of Chemicals [D27.505.259]
Radiopharmaceuticals [D27.505.259.843]
Molecular Mechanisms of Pharmacological Action [D27.505.519]
Radiopharmaceuticals [D27.505.519.871]
Specialty Uses of Chemicals [D27.720]
Laboratory Chemicals [D27.720.470]
Indicators and Reagents [D27.720.470.410]
Radiopharmaceuticals [D27.720.470.410.650]

Below are MeSH descriptors whose meaning is related to "Radiopharmaceuticals".

Below are MeSH descriptors whose meaning is more specific than "Radiopharmaceuticals".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Radiopharmaceuticals" by people in this website by year, and whether "Radiopharmaceuticals" was a major or minor topic of these publications.

Bar chart showing 319 publications over 30 distinct years, with a maximum of 18 publications in 2003 and 2007

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
1996	1	0	1
1997	4	1	5
1998	5	6	11
1999	5	6	11
2000	8	5	13
2001	7	5	12
2002	7	9	16
2003	1	17	18
2004	3	11	14
2005	6	7	13
2006	6	9	15
2007	7	11	18
2008	4	13	17
2009	6	7	13
2010	4	5	9
2011	5	12	17
2012	6	11	17
2013	7	7	14
2014	4	4	8
2015	3	9	12
2016	4	6	10
2017	2	5	7
2018	1	4	5
2019	3	4	7
2020	2	1	3
2021	6	5	11
2022	0	7	7
2023	1	3	4
2024	5	4	9
2025	1	1	2

Below are the most recent publications written about "Radiopharmaceuticals" by people in Profiles.

Patil S, Ayubcha C, Teichner E, Subtirelu R, Cho JH, Ghonim M, Ghonim M, Werner TJ, H?ilund-Carlsen PF, Alavi A, Newberg AB. Clinical Applications of PET Imaging in Alzheimer's Disease. PET Clin. 2025 Jan; 20(1):89-100.

View in: PubMed
Stauff E, Xu W, Kecskemethy HH, Langhans SA, Kandula VVR, Averill LW, Yue X. Tryptophan Kynurenine Pathway-Based Imaging Agents for Brain Disorders and Oncology-From Bench to Bedside. Biomolecules. 2025 Jan 01; 15(1).

View in: PubMed
Ivanidze J, Sharbatdaran A, McCalla A, Brandmaier A, Andreopoulou E, Cristofanilli M, Cigler T, Balogun OD, Magge RS, Liechty B, Karakatsanis NA, Nehmeh SA, Agee MA, Jean J, Osborne JR, Beal K, Schwartz TH, Pannullo SC, Knisely JPS, Ramakrishna R. [18F]-Fluoroestradiol (FES) brain PET in the evaluation of patients with estrogen receptor positive breast cancer and known or suspected brain metastases. Eur J Radiol. 2024 Dec; 181:111791.

View in: PubMed
Harrison DB, Phillips AL, Tansey JB, Clarke TJ, Wood CB, Nedzi L, Schwartz DL, Makowski L, Hayes DN, Newman G, Gleysteen JP. Brown Adipose Tissue Mimicking Head and Neck Cancer on PET Scan in a Patient on GLP-1 Drug. Laryngoscope. 2025 Feb; 135(2):741-743.

View in: PubMed
Chappidi MR, Iravani A, Stambler N, Baskaran S, DiPippo VA, Denes BS, Lin DW. Impact of Baseline Renal Insufficiency on Piflufolastat F-18 Performance and Investigation of Changes in Renal Function Following Piflufolastat F-18 Administration: Results From the OSPREY Trial. Clin Genitourin Cancer. 2024 Dec; 22(6):102223.

View in: PubMed
Xu W, Langhans SA, Johnson DK, Stauff E, Kandula VVR, Kecskemethy HH, Averill LW, Yue X. Radiotracers for Molecular Imaging of Angiotensin-Converting Enzyme 2. Int J Mol Sci. 2024 Aug 30; 25(17).

View in: PubMed
Zhou W, Du L, Brown DB, Shah RP, Sze DY. Outcomes Analysis of Yttrium-90 Radioembolization for Tumors Other Than Metastatic Colorectal Cancer from the Radiation-Emitting SIR-Spheres in Nonresectable (RESiN) Registry. J Vasc Interv Radiol. 2024 11; 35(11):1591-1600.e3.

View in: PubMed
Heholt J, Patel R, Vedaei F, Zabrecky G, Wintering N, Monti DA, Wang Z, Newberg AB, Mohamed FB. Simultaneous arterial spin labeling functional MRI and fluorodeoxyglucose PET in mild chronic traumatic brain injury. J Neuroradiol. 2024 Sep; 51(5):101211.

View in: PubMed
Kennedy AS, Brown DB, Fakih M, Jeyarajah R, Jones S, Liu D, Pinato DJ, Sangro B, Sharma NK, Sze DY, Van Cutsem E, Wasan HS. Multidisciplinary Delphi Consensus on Safety of Combining Transarterial Radioembolization with Yttrium-90 Microspheres with Systemic Anticancer Agents for the?Treatment of Liver Malignancy. J Vasc Interv Radiol. 2024 09; 35(9):1253-1267.e1.

View in: PubMed
Doyle PW, Workman CS, Grice JV, McGonigle TW, Huang S, Borgmann AJ, Baker JC, Duncan DP, Taylor JE, Brown DB. Predictive Dosimetry and Outcomes of Hepatocellular Carcinoma Treated by Yttrium-90 Resin Microsphere Radioembolization: A Retrospective Analysis Using Technetium-99m Macroaggregated Albumin SPECT/CT and Planning Software. J Vasc Interv Radiol. 2024 05; 35(5):689-698.e3.

View in: PubMed

People

Explore

Similar Concepts

Top Journals

The Thomas Jefferson University web site, its contents and programs, is provided for informational and educational purposes only and is not intended as medical advice nor is it intended to create any physician-patient relationship. Please remember that this information should not substitute for a visit or a consultation with a health care provider. The views or opinions expressed in the resources provided do not necessarily reflect those of Thomas Jefferson University, Thomas Jefferson University Hospital, or the Jefferson Health System or staff.
Please read our Privacy Statement